Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Argent Biopharma ( (AU:RGT) ) has shared an update.
Argent BioPharma Ltd. has announced a refinancing agreement with Mercer Street Global Opportunity Fund, LLC, which involves amending the minimum conversion price of 250,000 convertible notes from A$10.00 to A$0.11. This adjustment is part of a broader strategy to amend terms of existing convertible note facilities, potentially impacting the company’s financial flexibility and market positioning.
More about Argent Biopharma
Argent BioPharma Limited (ASX: RGT) is a clinical-stage biopharmaceutical company specializing in neuroimmunology and advanced nanomedicine. The company focuses on developing cannabinoid-based therapeutics and neuroimmune modulation, with a pipeline that includes products like CannEpil®, CogniCann®, and CimetrA® targeting CNS disorders and immune-related conditions.
YTD Price Performance: -20.83%
Average Trading Volume: 554
Technical Sentiment Signal: Buy
Current Market Cap: $6.65M
For a thorough assessment of RGT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue